___

• 1. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet 2005;366(9480):155-68. [Crossref]
• 2. Vasan RS, Shrivastava S, Vijayakumar M, Narang R, Lister BC, Narula J. Echocardiographic evaluation of patients with acute rheumatic fever and rheumatic carditis. Circulation 1996;94:73-82. [Crossref]
• 3. Folger GM Jr, Hajar R, Robida A, Hajar HA. Occurrence of valvular heart disease in acute rheumatic fever without evidence carditis: color-flow Doppler identification. Br Heart J 1992;67:434-438. [Crossref]
• 4. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988;60(4):299-308. [Crossref]
• 5. Macfarlane DP, Yu N, Leese GP. Subclinical and asymptomatic parathyroid disease: implications of emerging data. Lancet Diabetes Endocrinol 2013;1:329-40. [Crossref]
• 6. Oztürk D, Ozcan Çelebi O, Ulusoy FV, Aydoğdu S. The relationship between serum parathormone levels and the severity of coronary artery disease. Turk Kardiyol Dern Ars 2012;40(7):589-94. [Crossref]
• 7. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003;89(5):552-72. [Crossref]
• 8. Yavuz B, Sen O, Deveci OS, Akin KO, Dal K, Ata N, et al. Serum 25-hydroxyvitamin D levels are correlated with mitral valve calcification score in patients with rheumatic mitral stenosis. J Heart Valve Dis 2012;21:570-5.
• 9. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006 Sep;92(1):39-48. [Crossref]
• 10. Schinke T, Karsenty G. Vascular calcification a passive process in need of inhibitors. Nephrol Dial Transplant 2000;15(9):1272-4. [Crossref]
• 11. Linhartová K, Veselka J, Sterbáková G, Racek J, Topolcan O, Cerbák R. Parathyroid Hormone and Vitamin D Levels Are Independently Associated With Calcific Aortic Stenosis. Circ J 2008;72(2):245-50. [Crossref]
• 12. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020;143(5):e229. [Crossref]
• 13. Froude J, Gibofsky A, Buskirk DR, Khanna A, Zabriskie JB. Cross-reactivity between streptococcus and human tissue: a model of molecular mimicry and autoimmunity. Curr Top Microbiol Immunol 1989;145:5-26. [Crossref]
• 14. Mukhopadhyay S, Varma S, Mohan Kumar HN, Yusaf J, Goyal M, Mehta V, et al. Circulating level of regulatory T cells in rheumatic heart disease: an observational study. Indian Heart J 2016;68(3):342-8. [Crossref]
• 15. Wen Y, Zeng Z, Gui C, Gui C, Li L, Li W. Changes in the expression of Th17 cellassociated cytokines in the development of rheumatic heart disease. Cardiovasc Pathol 2015;24(6):382-7. [Crossref]
• 16. Bas HD, Baser K, Yavuz E, Bolayir HA, Yaman B, Unlu S, et al. A shift in the balance of regulatory T and T helper 17 cells in rheumatic heart disease. J Invest Med 2014;62(1):78-83. [Crossref]
• 17. Kaden JJ, Kilic R, Sarikoc A, Hagl S, Lang S, Hoffmann U, et al. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. Int J Mol Med 2005;16(5):869-72. [Crossref]
• 18. Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000;102(21):2636-42. [Crossref]
• 19. Cantorna MT, Snyder L, Lin YD, Yang L. Vitamin D and 1,25(OH)2D regulation of T cells. Nutrients 2015;7(4):3011-21. [Crossref]
• 20. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1.25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000;374(2):334-8. [Crossref]
• 21. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and Autoimmunity: New Aetiological and Therapeutic Considerations. Ann Rheum Dis 2007;66(9):1137-42. [Crossref]
• 22. Korf H, Wenes M, Stijlemans B, Takiishi T, Robert S, Miani M, et al. 1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism. Immunobiology 2012;217(12):1292-300. [Crossref]
• 23. Rigby WF, Yirinec B, Oldershaw RL, Fanger MW. Comparison of the effects of 1.25 dihydroxyvitamin D3 on T lymphocyte subpopulations. Eur J Immunol 1987;17(4):563-6. [Crossref]
• 24. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1.25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983;221(4616):1181-3. [Crossref]
• 25. Joshi S, Pantalena LC, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C, et al. 1.25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 2011;31(17):3653-69. [Crossref]
• 26. Overbergh L, Decallonne B, Waer M, Rutgeerts O, Valckx D, Casteels KM, et al. 1alpha.25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65. Diabetes 2000;49(8):1301-7. [Crossref]
• 27. Yusuf J, Jothinath P, Mukhopadhyay S, Vignesh V, Tyagi S. Evaluation of Serum 25-hydroxyvitamin D levels in calcific rheumatic mitral stenosis- a cross sectional study. Indian Heart J 2018;70(2):206-13. [Crossref]
• 28. Macfarlane DP, Yu N, Leese GP. Subclinical and asymptomatic parathyroid disease: implications of emerging data. Lancet Diabetes Endocrinol 2013;1:329-40. [Crossref]
• 29. Cheng SP, Liu CL, Liu TP, Hsu YC, Lee JJ. Association between parathyroid hormone levels and inflammatory markers among US adults. Mediators Inflamm 2014:709024. [Crossref]
• 30. Eren E, Ellidag HY, Cekin Y, Ayoglu RU, Sekercioglu AO, Yılmaz N. Heart valve disease: the role of calcidiol deficiency, elevated parathyroid hormone levels and oxidative stress in mitral and aortic valve insufficiency. Redox Rep 2014;19(1):34-9. [Crossref]